Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_assertion type Assertion NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_head.
- NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_assertion wasGeneratedBy ECO_0000203 NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_provenance.
- NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_assertion wasDerivedFrom befree-20150227 NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_provenance.
- NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_assertion SIO_000772 15988530 NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_provenance.
- NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_assertion evidence source_evidence_literature NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_provenance.
- NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_provenance.